Radionetics Oncology
Jean-Michel V. is an experienced professional in the field of chemistry, currently serving as Senior Vice President of Chemistry at Radionetics Oncology since July 2024. Prior to this role, Jean-Michel held the position of Vice President of Chemistry at Erasca, Inc. from March 2019 to August 2024, and served as Vice President of Chemistry at IGNYTA, Inc. from June 2013 to December 2018. Additional roles include Head of Medicinal Chemistry at Ruga Corporation, Vice President of Discovery Chemistry at Ardea Biosciences, Associate Director of Chemistry at Valeant Pharmaceuticals, Senior Investigator of Chemistry at Merck, and Senior Research Scientist at SIBIA Neurosciences. Jean-Michel earned a Ph.D. in Chemistry from the University of Strasbourg, completing studies from 1983 to 1990.
This person is not in any teams
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.